



BioSim[™] anti-Denosumab (Prolia®) (Human) ELISA Kit

rev 04/20

(Catalog # E4394-100, 100 assays, Store at 4°C)

I. Introduction:

Denosumab (Prolia®) is a human monoclonal antibody that binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision's BioSim[™] anti-Denosumab ELISA kit is designed to detect antibody against Denosumab with high specificity and sensitivity in biological matrices.

II. Application:

This ELISA kit is used for *in vitro* qualitative determination of antibody against Denosumab in serum and plasma Cross Reactivity: Denosumab (Prolia®) infusion camouflages/masks the presence of antibody to Denosumab (ATD) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATD. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Denosumab.

III. Sample Type:

Human serum and plasma

IV. Kit Contents:

| Components | E4394-100 | Part No. |
|-----------------------------|-----------|-------------|
| Micro ELISA Plate | 1 plate | E4394-100-1 |
| Positive Control | 0.3 ml | E4394-100-2 |
| Negative Control | 1 ml | E4394-100-3 |
| Assay Buffer | 12 ml | E4394-100-4 |
| Peroxidase Conjugate | 12 ml | E4394-100-5 |
| TMB substrate (Avoid light) | 12 ml | E4394-100-6 |
| Stop Solution | 12 ml | E4394-100-7 |
| Wash buffer (20X) | 50 ml | E4394-100-8 |
| Plate sealers | 2 | E4394-100-9 |

V. User Supplied Reagents and Equipment:

- Microplate reader capable of measuring absorbance at 450 nm
- Precision pipettes with disposable tips
- · Clean eppendorf tubes for preparing standards or sample dilutions
- Absorbent paper

VI. Storage and Handling:

The entire kit may be stored at 4°C for up to 12 months from the date of shipment.

VII. Reagent and Sample Preparation:

Note: Before using the kit, spin tubes and bring down all components to the bottom of tubes.

- 1. **Wash Buffer**: Dilute the 20X Wash Buffer to 1X solution in ddH₂O (10 ml of Wash Buffer stock to 190 ml of ddH₂O). Mix the 1X solution thoroughly by vortex manually. The working stock can be stable for 2 weeks after preparation at 4°C.
- 2. Samples preparation: The usual precautions for venipuncture should be observed. Samples are stable at 4°C for 7 days and -20°C for 6 months. Avoid freeze-and-thaw cycle.

VIII. Assay Protocol:

Note: Bring all reagents, microplate and samples to room temperature 15 minutes prior to the assay.

It is recommended that all standards and samples be run at least in duplicate.

- A standard curve must be run with each assay.
- 1. Prepare all reagents, samples and standards as instructed in section VII.
- 2. Pipette 100 µl of Assay Buffer into each of the wells to be used.
- 3. Add 10 μl of **negative control** (2 wells), **positive control**, and **samples** into appropriate wells. Cover wells and incubate for 60 minutes at room temperature (RT).
- 4. Discard incubation solution. Wash plate 3 times each with 300 µl of diluted **Wash Buffer**. Remove excess solution by tapping the inverted plate on a paper towel.
- 5. Add 100 µl of Peroxidase Conjugate into each well. Cover wells with adhesive plate sealer and incubate at RT for 60 minutes.
- 6. Discard the solution and wash the wells as step 3.
- 7. Add 100 µl of 1X TMB substrate solution and incubate the plate in dark at RT for 20 minutes
- 8. Add 100 µl of Stop solution to stop the reaction





9. Read the absorbance in micro plate reader set to 450 nm within 20 minutes. (reference wavelength to 650 nm)

IX. QUALITATIVE INTERPRETATION:

- For the run to be valid, the OD 450/650 nm of positive control should be >1,500 and the OD 450/650 nm of each negative control should be <0.150, if not, improper technique or reagent deterioration may be suspected and the run should be repeated.
- If "Sample OD_{450/650} / Negative Control OD_{450/650}" is < 3, the sample is NEGATIVE for Antibody to Denosumab.
- If "Sample OD450/650 / Negative Control OD450/650" is ≥ 3, the sample is POSITIVE for Antibody to Denosumab.

X. RELATED PRODUCTS:

- BioSim[™] Rituximab (Mabthera®) (Human) ELISA Kit (Cat. No. E4371-100)
- BioSim[™] Adalimumab (Humira®) (Human) ELISA Kit (Cat. No. E4372-100)
- BioSim[™] Bevacizumab (Avastin[®]) (Human) ELISA Kit (Cat. No. E4373-100)
- BioSim[™] Etanercept (Enbrel®) (Human) ELISA Kit (Cat. No. E4374-100)
- BioSim[™] Infliximab (Remicade[®]) (Human) ELISA Kit (Cat. No. E4375-100)
- BioSim[™] Trastuzumab(Herceptin®)(Human) ELISA Kit (Cat. No. E4376-100)
- BioSim[™] Golimumab (Simponi®)(Human) ELISA Kit (Cat. No. E4377-100)
- BioSim[™] Infliximab (Remsima®)(Human) ELISA Kit (Cat. No. E4378-100)
- BioSim[™] Cetuximab (Erbitux®)(Human) ELISA Kit (Cat. No. E4379-100)
- BioSim[™] Denosumab (Prolia®)(Human) ELISA Kit (Cat. No. E4380-100)
- BioSim[™] Omalizumab (Xolair®)(Human) ELISA Kit (Cat. No. E4381-100)
- BioSim[™] Nivolumab (Opdivo®)(Human) ELISA Kit (Cat. No. E4382-100)
- BioSim[™] Pembrolizumab (Keytruda®)(Human) ELISA Kit (Cat. No. E4383-100)
- BioSim[™] Ipilimumab (Yervoy®)(Human) ELISA Kit (Cat. No. E4384-100)
- BioSim[™] Rituximab (Mabthera®) (Human) ELISA Kit (Cat. No. E4385-100)
- BioSim[™] Trastuzumab (Herceptin[®]) (Human) ELISA Kit (Cat. No. E4386-100)
- BioSim[™] Infliximab (Remicade®) (Human) ELISA Kit (Cat. No. E4387-100)
- BioSim[™] Adalimumab (Humira®) (Human) ELISA Kit (Cat. No. E4388-100)
- BioSim[™] Bevacizumab (Avastin®) (Human) ELISA Kit (Cat. No. E4389-100)
- BioSim[™] Infliximab (Remsima®) (Human) ELISA Kit (Cat. No. E4390-100)
- BioSim[™] Cetuximab (Erbitux®) (Human) ELISA Kit (Cat. No. E4391-100)
- BioSim[™] Etanercept (Enbrel®) (Human) ELISA Kit (Cat. No. E4392-100)
- BioSim[™] Golimumab (Simponi[®]) (Human) ELISA Kit (Cat. No. E4393-100)
- BioSim[™] Denosumab (Prolia®) (Human) ELISA Kit (Cat. No. E4394-100)
- BioSim[™] Omalizumab (Xolair®) (Human) ELISA Kit (Cat. No. E4395-100)
- BioSim[™] Nivolumab (Opdivo®) (Human) ELISA Kit (Cat. No. E4396-100)
- BioSim[™] Pembrolizumab (Keytruda®) (Human) ELISA Kit (Cat. No. E4397-100)
- BioSim[™] Ipilimumab (Yervoy[®]) (Human) ELISA Kit (Cat. No. E4398-100)
- BioSim[™] Filgrastim (Herceptin®) (Human) ELISA Kit (Cat. No. E4399-100)